Skip to main content

Advertisement

SpringerLink
Log in

Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ferrari C, Maggialetti N, Masi T, Nappi AG, Santo G, NiccoliAsabella A, Rubini G. Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET/CT: a literature overview. J Personalized Med. 2021;11(3):217. https://doi.org/10.3390/jpm11030217.

    Article  Google Scholar 

  2. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385–96. https://doi.org/10.1093/annonc/mdz003.

    Article  CAS  PubMed  Google Scholar 

  3. Danylesko I, Shouval R, Shem-Tov N, Yerushalmi R, Jacoby E, Besser MJ, Shimoni A, Davidson T, Beider K, Mevorach D, Fried S. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant. 2021;56(5):1134–43. https://doi.org/10.1038/s41409-020-01156-y.

    Article  CAS  PubMed  Google Scholar 

  4. Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, Zhang Y, Zhang Y, Chen D, Wu Z, Xiao L. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1092–8. https://doi.org/10.1016/j.bbmt.2019.02.008.

    Article  CAS  PubMed  Google Scholar 

  5. Boursier C, Perrin M, Bordonne M, Campidelli A, Verger A. Early 18F-FDG PET flare-up phenomenon after CAR T-cell therapy in lymphoma. Clin Nucl Med. 2021. https://doi.org/10.1097/RLU.0000000000003870.

    Article  Google Scholar 

  6. Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D’Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607–15. https://doi.org/10.1182/bloodadvances.2020003001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cohen D, Luttwak E, Beyar-Katz O, Hazut Krauthammer S, Bar-On Y, Amit O, Gold R, Perry C, Avivi I, Ram R, Even-Sapir E. [18F] FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre-and post-treatment studies. Eur J Nucl Med Mol Imaging. 2021;4:1. https://doi.org/10.1007/s00259-021-05551-5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizmann St, 6423906, Tel Aviv, Israel

    Dan Cohen & Einat Even-Sapir

  2. Institute of Hematology, Tel-Aviv Sourasky Medical Center, 6 Weizmann St, 6423906, Tel Aviv, Israel

    Ofrat Beyar-Katz & Chava Perry

  3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Ofrat Beyar-Katz, Einat Even-Sapir & Chava Perry

Authors
  1. Dan Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ofrat Beyar-Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Einat Even-Sapir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chava Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Einat Even-Sapir.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Hematology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, D., Beyar-Katz, O., Even-Sapir, E. et al. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion. Eur J Nucl Med Mol Imaging 49, 2447–2449 (2022). https://doi.org/10.1007/s00259-022-05722-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-022-05722-y

Search

Navigation